AI Engines For more Details: Perplexity Kagi Labs You
Lowering Cholesterol: Atorvastatin belongs to a class of medications known as statins, which work by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis. By reducing cholesterol production in the liver, atorvastatin helps lower total cholesterol, LDL cholesterol (often referred to as "bad" cholesterol), and triglyceride levels.
Cardiovascular Risk Reduction: By lowering cholesterol levels, especially LDL cholesterol, atorvastatin helps reduce the risk of cardiovascular events such as heart attacks, strokes, and coronary artery disease. It is often prescribed for individuals with a history of cardiovascular disease or those at high risk of developing it.
Prevention of Atherosclerosis: Atherosclerosis is a condition characterized by the buildup of plaque in the arteries, leading to narrowed and hardened arteries. Atorvastatin helps prevent the progression of atherosclerosis by reducing the accumulation of cholesterol-rich plaque in the arterial walls.
Treatment of Hyperlipidemia: Atorvastatin is used to treat various forms of hyperlipidemia, including familial hypercholesterolemia, a genetic condition characterized by high levels of LDL cholesterol from birth.
Dosage Forms: Atorvastatin is available in oral tablet form and is typically taken once daily. It comes in various strengths, allowing for individualized dosing based on the patient's cholesterol levels and cardiovascular risk factors.
Combination Therapies: Atorvastatin may be prescribed alone or in combination with other lipid-lowering medications, such as ezetimibe or fenofibrate, to achieve optimal cholesterol management in certain individuals.
Side Effects: Common side effects of atorvastatin may include muscle aches, joint pain, gastrointestinal symptoms (such as nausea, diarrhea, or constipation), headache, and fatigue. In rare cases, it may cause liver enzyme abnormalities or muscle damage (rhabdomyolysis), particularly at higher doses or when used in combination with certain medications.
Monitoring: Regular monitoring of liver function tests and creatine kinase levels may be recommended during atorvastatin therapy, especially in patients at higher risk of adverse effects. This helps healthcare providers detect and manage any potential side effects promptly.
Contraindications: Atorvastatin is contraindicated in individuals with active liver disease or unexplained persistent elevations in liver enzymes. It should also be avoided in pregnant and breastfeeding women due to potential risks to the fetus or infant.
Long-Term Use: Atorvastatin is generally safe for long-term use when prescribed appropriately and monitored regularly. It is often considered a lifelong therapy for individuals with high cholesterol or a history of cardiovascular disease.
Drug Interactions: Atorvastatin may interact with certain medications, including some antibiotics, antifungal agents, immunosuppressants, and drugs metabolized by the cytochrome P450 system. It is essential to inform healthcare providers about all medications, supplements, and herbal products being taken to minimize the risk of drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| ADHD | 2.4 | 0.6 | 3 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.5 | 0.9 | 1.78 |
| Allergies | 3.6 | 2.2 | 0.64 |
| Allergy to milk products | 1.7 | 0.7 | 1.43 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.4 | 5.5 | -0.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 0.6 | 4.5 |
| Ankylosing spondylitis | 3.6 | 1.2 | 2 |
| Anorexia Nervosa | 1.1 | 2.8 | -1.55 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 3.7 | 2.2 | 0.68 |
| Atherosclerosis | 1 | 2 | -1 |
| Atrial fibrillation | 3 | 1.9 | 0.58 |
| Autism | 8.9 | 8 | 0.11 |
| Autoimmune Disease | 0.3 | 0.7 | -1.33 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 1.2 | 1.1 | 0.09 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 2.6 | 2 | 0.3 |
| Celiac Disease | 2.6 | 2.5 | 0.04 |
| Cerebral Palsy | 1.3 | 1 | 0.3 |
| Chronic Fatigue Syndrome | 3 | 5.6 | -0.87 |
| Chronic Kidney Disease | 3.1 | 3.1 | 0 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1.4 | -1 |
| Chronic Urticaria (Hives) | 0.5 | 1.7 | -2.4 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.5 | 1.3 | 0.92 |
| Colorectal Cancer | 5.1 | 1.9 | 1.68 |
| Constipation | 1.3 | 0.7 | 0.86 |
| Coronary artery disease | 1.5 | 2.6 | -0.73 |
| COVID-19 | 6.8 | 10.1 | -0.49 |
| Crohn's Disease | 7.1 | 5.9 | 0.2 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 1.3 | 1.1 | 0.18 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 8.3 | 8.6 | -0.04 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.1 | 1 | 0.1 |
| Endometriosis | 2 | 1.4 | 0.43 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.6 | 2.3 | 0.13 |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 2.6 | 2.3 | 0.13 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3.6 | 0.06 |
| gallstone disease (gsd) | 2.4 | 1 | 1.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 2.4 | 1.6 | 0.5 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.1 | 1 | 0.1 |
| Graves' disease | 1 | 2.4 | -1.4 |
| Gulf War Syndrome | 0.9 | 1.9 | -1.11 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3.1 | 1.7 | 0.82 |
| Heart Failure | 2.7 | 1.8 | 0.5 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 1.3 | 1.3 | |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.6 | 2 | -2.33 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.4 | 4.3 | 0.02 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 2.6 | 2.6 | |
| IgA nephropathy (IgAN) | 1.3 | 3.5 | -1.69 |
| Inflammatory Bowel Disease | 5.9 | 7.6 | -0.29 |
| Insomnia | 1.6 | 2.9 | -0.81 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 5.5 | 5 | 0.1 |
| ischemic stroke | 1.1 | 1.1 | 0 |
| Liver Cirrhosis | 5.2 | 3.9 | 0.33 |
| Long COVID | 5.4 | 5.9 | -0.09 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.3 | -1.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.5 | 2.1 | -3.2 |
| ME/CFS without IBS | 2 | 2.1 | -0.05 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 1 | -2.33 |
| Metabolic Syndrome | 5.6 | 6.5 | -0.16 |
| Mood Disorders | 8.1 | 6.5 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.4 | 6.2 | -0.15 |
| Multiple system atrophy (MSA) | 1.8 | 0.1 | 17 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.8 | -8.33 |
| Neuropathy (all types) | 1.2 | 1.1 | 0.09 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 4.1 | -0.14 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.3 | 4.33 |
| Obesity | 8.8 | 6.8 | 0.29 |
| obsessive-compulsive disorder | 3.6 | 4.6 | -0.28 |
| Osteoarthritis | 2.2 | 1.1 | 1 |
| Osteoporosis | 1.3 | 1.9 | -0.46 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.7 | 5.9 | 0.14 |
| Polycystic ovary syndrome | 5.5 | 2.2 | 1.5 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 1.3 | 2.9 | -1.23 |
| Psoriasis | 2.6 | 4 | -0.54 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.1 | 3.7 | 0.65 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 4.6 | 2.7 | 0.7 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 1.7 | 2.3 | -0.35 |
| Sleep Apnea | 1.3 | 1.5 | -0.15 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 2.5 | 3 | -0.2 |
| Systemic Lupus Erythematosus | 3.3 | 1.9 | 0.74 |
| Tic Disorder | 1.3 | 1.5 | -0.15 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 2.9 | 2.3 | 0.26 |
| Type 2 Diabetes | 6.6 | 6 | 0.1 |
| Ulcerative colitis | 4.1 | 6.4 | -0.56 |
| Unhealthy Ageing | 4.1 | 2.7 | 0.52 |
| Vitiligo | 1.8 | 1.7 | 0.06 |
